TEL AVIV: Aidoc has closed a $150 million Series E to expand its clinical AI imaging platform across hospital systems worldwide.
The Israeli startup’s algorithms analyze radiology scans in real time, flagging critical conditions like strokes, pulmonary embolisms, and brain bleeds within minutes.
Already deployed across 1,500+ hospitals and processing over 25 million scans annually, Aidoc filters urgent cases for radiologists, with documented improvements in patient outcomes. Studies show measurable improvements in patient outcomes from faster diagnoses.
The Series E lands as medical AI enters institutional-grade deployment phases. OpenEvidence recently raised $250 million at a $12 billion valuation for clinical decision support. Hospital procurement teams increasingly view AI tools as standard infrastructure.
Aidoc’s platform also expands beyond radiology into broader clinical workflows. New modules target cardiology, oncology, and operating room coordination tasks. The company positions itself as a horizontal AI layer for hospital operations.
The funding follows growing regulatory acceptance of AI diagnostic tools globally. The FDA has cleared multiple Aidoc algorithms for clinical use already. European and Asian regulators continue expanding pathways for medical AI approval.
“Healthcare AI works best when it amplifies clinician judgment, not replaces it,” says an Aidoc executive about the round.
Competition intensifies across medical imaging AI rapidly. RapidAI, Viz.ai, and HeartFlow all push competing diagnostic platforms aggressively. Each company races to build clinical evidence and hospital relationships at scale.
Aidoc plans to use proceeds for clinical validation studies and geographic expansion. New markets in Asia and Latin America represent significant growth opportunities. The company also wants to deepen integrations with electronic health record systems.
Hospital adoption of AI imaging tools continues accelerating worldwide.
Previous
